EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitLeserbrief

Enhancing glioma care with advanced imaging: T2-FLAIR mismatch as a predictive biomarker in IDH-mutant astrocytoma

Manal Nadeem, Umer Bin Shahzad, Nawal Tahir, Ayesha Areej

Neurosurgical Review · 2024

DOI: 10.1007/s10143-024-02748-8 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Neurosurgical Review, 2024. Verfasst von Manal Nadeem und 3 weiteren Autor:innen. Beteiligte Einrichtung: Islamic International Medical College, Rawalpindi, MBBS, Pakistan. drmanalnadeem@gmail.com. Hauptthemen laut MEDLINE: Brain Neoplasms, Isocitrate Dehydrogenase, Astrocytoma, Glioma. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 5 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The study highlights that diffuse glioma, a prevalent type of brain tumor, affect approximately 100,000 individuals worldwide each year. IDH-mutant astrocytoma and oligodendrogliomas typically have a more favorable prognosis compared to IDH-wildtype glioblastomas. However, many IDH-mutant astrocytoma has the potential to progress to grade 4 glioblastomas, leading to a less favorable prognosis. In a recent investigation, Shumpei Onishi et al. examined the T2-FLAIR mismatch sign as a possible imaging biomarker for assessing CDKN2A status in non-enhancing IDH-mutant astrocytoma. The findings indicate that the T2-FLAIR mismatch sign is linked to CDKN2A-intact astrocytoma, providing a valuable tool for diagnostic and prognostic purposes. Additionally, the use of Indocyanine Green (ICG) for real-time visualization during neurosurgical procedures demonstrates potential, though it may have limitations in specificity. While these advancements offer promise in glioma management, there remains a critical need for larger, standardized studies to validate these findings and further improve treatment outcomes.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Brain NeoplasmsIsocitrate DehydrogenaseAstrocytomaGliomaMutationHumansMagnetic Resonance ImagingBiomarkers, TumorPrognosis

Stichwörter der Autor:innen

CDKN2A deletionDiffuse gliomasIDH-mutant astrocytomaImaging biomarkersRadiological featuresSuper T2-FLAIR mismatch signT2-FLAIR mismatch sign

Substanzen

Isocitrate DehydrogenaseBiomarkers, Tumor

Autor:innen und Institutionen

  • Islamic International Medical College, Rawalpindi, MBBS, Pakistan. drmanalnadeem@gmail.com.
  • Islamic International Medical College, Rawalpindi, MBBS, Pakistan.

Zitieren

APA

Nadeem, M., Shahzad, U. B., Tahir, N., & Areej, A. (2024). Enhancing glioma care with advanced imaging: T2-FLAIR mismatch as a predictive biomarker in IDH-mutant astrocytoma. Neurosurgical Review. https://doi.org/10.1007/s10143-024-02748-8

Vancouver

Nadeem M, Shahzad UB, Tahir N, Areej A. Enhancing glioma care with advanced imaging: T2-FLAIR mismatch as a predictive biomarker in IDH-mutant astrocytoma. Neurosurgical Review. 2024. doi:10.1007/s10143-024-02748-8

BibTeX
@article{Nadeem2024,
  author = {Nadeem, Manal and Shahzad, Umer Bin and Tahir, Nawal and Areej, Ayesha},
  title = {Enhancing glioma care with advanced imaging: T2-FLAIR mismatch as a predictive biomarker in IDH-mutant astrocytoma},
  journal = {Neurosurgical Review},
  year = {2024},
  doi = {10.1007/s10143-024-02748-8}
}
Kostenlos starten →